Enhertu Granted Priority Review in the US as Post-Neoadjuvant Treatment for Patients With HER2-Positive Early Breast Cancer
March 10, 2026
March 10, 2026
WILMINGTON, Delaware, March 10 -- AstraZeneca, a biopharmaceutical company, issued the following news release:
* * *
ENHERTU(R) (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US as post-neoadjuvant treatment for patients with HER2-positive early breast cancer
Based on DESTINY-Breast05 Phase III trial results which showed ENHERTU reduced the risk of invasive disease recurrence or death by 53 compared with T-DM1
If approved, As . . .
* * *
ENHERTU(R) (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US as post-neoadjuvant treatment for patients with HER2-positive early breast cancer
Based on DESTINY-Breast05 Phase III trial results which showed ENHERTU reduced the risk of invasive disease recurrence or death by 53 compared with T-DM1
If approved, As . . .